Viracta Therapeutics, Inc., a clinical-stage precision oncology company dedicated to treating and preventing virus-associated cancers that affect patients globally, has terminated its employees and is winding down its operations. The company is also actively exploring potential strategic alternatives for its development programs.

The board of directors has appointed Craig R. Jalbert, a seasoned accounting professional with over 30 years of experience, as the Company’s CEO, President, CFO, Treasurer, and Corporate Secretary. Jalbert has been a principal at the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. Throughout his career, he has specialized in distressed businesses and has served as an officer and director for numerous firms during their winding-down phases.

This news comes after Viracta elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas in December.